Galecto Inc (GLTO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galecto Inc (GLTO) has a cash flow conversion efficiency ratio of -0.392x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.62 Million) by net assets ($6.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Galecto Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Galecto Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Galecto Inc (GLTO) financial obligations for a breakdown of total debt and financial obligations.
Galecto Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galecto Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korea Computer Terminal Inc
KQ:089150
|
0.117x |
|
Barfresh Food Group Inc
NASDAQ:BRFH
|
-0.311x |
|
Live Ventures Inc
NASDAQ:LIVE
|
0.103x |
|
I-Hwa Industrial Co Ltd
TW:1456
|
-0.100x |
|
Globetronics Tech Bhd
KLSE:7022
|
-0.034x |
|
Indiabulls Enterprises Limited
NSE:IEL
|
N/A |
|
Compal Broadband Networks Inc
TW:6674
|
-0.041x |
|
Royal Road Minerals Ltd
V:RYR
|
-0.133x |
Annual Cash Flow Conversion Efficiency for Galecto Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Galecto Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Galecto Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $15.83 Million | $-18.62 Million | -1.176x | -3.04% |
| 2023-12-31 | $32.33 Million | $-36.91 Million | -1.142x | -64.22% |
| 2022-12-31 | $61.75 Million | $-42.93 Million | -0.695x | -55.80% |
| 2021-12-31 | $117.22 Million | $-52.31 Million | -0.446x | -93.30% |
| 2020-12-31 | $165.49 Million | $-38.20 Million | -0.231x | +42.10% |
| 2019-12-31 | $48.47 Million | $-19.33 Million | -0.399x | +10.71% |
| 2018-12-31 | $30.66 Million | $-13.69 Million | -0.447x | -- |
About Galecto Inc
Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, In… Read more